Corrigendum to "Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking" [Drug Alcohol Depend. 89/1 (2007) 24-33] (DOI:10.1016/j.drugalcdep.2006.11.012);Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking

Drug and Alcohol Dependence

Volumn 89, Issue 1, 2007, Pages 24-33

  Mwenifumbo, Jill C ^a   Sellers, Edward M ^a   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcohol and nicotine; Black African descent; Gender; Marijuana; Smoking

Indexed keywords

NICOTINE;

ADULT; AFRICA; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; ETHNIC OR RACIAL ASPECTS; FEMALE; GENETIC VARIABILITY; HUMAN; MALE; METABOLISM; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

CANNABIS SATIVA;

EID: 34247165002     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.04.004     Document Type: Erratum

References (69)

1. Agurell S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespie H., and Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38 (1986) 21-43
2. Ait-Daoud N., Wiesbeck G.A., Bienkowski P., Li M.D., Pfutzer R.H., Singer M.V., Lesch O.M., and Johnson B.A. Comorbid alcohol and nicotine dependence: from the biomolecular basis to clinical consequences. Alcohol. Clin. Exp. Res. 29 (2005) 1541-1549
3. Batel P., Pessione F., Maitre C., and Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 90 (1995) 977-980
4. Beierle I., Meibohm B., and Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 37 (1999) 529-547
5. Benowitz N., and Hatsukami D. Gender differences in the pharmacology of nicotine addiction. Addict. Biol. 3 (1998) 383-404
6. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 597-613
7. Benowitz N.L., and Jacob III P. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J. Pharmacol. Exp. Ther. 234 (1985) 153-155
8. Benowitz N.L., and Jacob III P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56 (1994) 483-493
9. Benowitz N.L., and Jacob III P. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin. Pharmacol. Ther. 67 (2000) 653-659
10. Benowitz N.L., Jacob III P., Jones R.T., and Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J. Pharmacol. Exp. Ther. 221 (1982) 368-372
11. Benowitz N.L., and Jones R.T. Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin. Pharmacol. Ther. 22 (1977) 259-268
12. Benowitz N.L., Jones R.T., and Jacob III P. Additive cardiovascular effects of nicotine and ethanol. Clin. Pharmacol. Ther. 40 (1986) 420-424
13. Benowitz N.L., Lessov-Schlaggar C.N., Swan G.E., and Jacob III P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79 (2006) 480-488
14. Benowitz N.L., Perez-Stable E.J., Fong I., Modin G., Herrera B., and Jacob III P. Ethnic differences in N-glucuronidation of nicotine and cotinine. J. Pharmacol. Exp. Ther. 291 (1999) 1196-1203
15. Benowitz N.L., Perez-Stable E.J., Herrera B., and Jacob III P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J. Natl. Cancer Inst. 94 (2002) 108-115
16. Benowitz N.L., Pomerleau O.F., Pomerleau C.S., and Jacob III P. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob. Res. 5 (2003) 621-624
17. Dempsey D., Tutka P., Jacob III P., Allen F., Schoedel K., Tyndale R.F., and Benowitz N.L. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76 (2004) 64-72
18. Denton T.T., Zhang X., and Cashman J.R. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem. Pharmacol. 67 (2004) 751-756
19. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., and Kamataki T. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25 (2004) 2451-2458
20. Fukami T., Nakajima M., Higashi E., Yamanaka H., McLeod H.L., and Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem. Pharmacol. 70 (2005) 801-808
21. Fukami T., Nakajima M., Yoshida R., Tsuchiya Y., Fujiki Y., Katoh M., McLeod H.L., and Yokoi T. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin. Pharmacol. Ther. 76 (2004) 519-527
22. Giovino G.A., Schooley M.W., Zhu B.P., Chrismon J.H., Tomar S.L., Peddicord J.P., Merritt R.K., Husten C.G., and Eriksen M.P. Surveillance for selected tobacco-use behaviors-United States, 1900-1994. MMWR CDC Surveill Summ. 43 (1994) 1-43
23. Hadidi H., Zahlsen K., Idle J.R., and Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 35 (1997) 903-907
24. Henningfield J.E., Miyasato K., and Jasinski D.R. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J. Pharmacol. Exp. Ther. 234 (1985) 1-12
25. Huestis M.A., Henningfield J.E., and Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 16 (1992) 276-282
26. Hukkanen J., Jacob III P., and Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57 (2005) 79-115
27. Johnstone E., Benowitz N., Cargill A., Jacob R., Hinks L., Day I., Murphy M., and Walton R. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin. Pharmacol. Ther. 80 (2006) 319-330
28. Kirby G.M., Batist G., Alpert L., Lamoureux E., Cameron R.G., and Alaoui-Jamali M.A. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol. Pathol. 24 (1996) 458-467
29. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., and Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79 (2006) 600-608
30. Lopez-Arrieta J.M., Rodriguez J.L., and Sanz F. Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst. Rev. (2001) CD001749
31. Malaiyandi V., Lerman C., Benowitz N.L., Jepson C., Patterson F., and Tyndale R.F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11 (2006) 400-409
32. McGrath J., McDonald J.W., and Macdonald J.K. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2004) CD004722
33. Messina E.S., Tyndale R.F., and Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282 (1997) 1608-1614
34. Minematsu N., Nakamura H., Furuuchi M., Nakajima T., Takahashi S., Tateno H., and Ishizaka A. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur. Respir. J. 27 (2006) 289-292
35. Molander L., Hansson A., and Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clin. Pharmacol. Ther. 69 (2001) 57-65
36. Nakajima M., Fukami T., Yamanaka H., Higashi E., Sakai H., Yoshida R., Kwon J.T., McLeod H.L., and Yokoi T. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80 (2006) 282-297
37. Nakajima M., Itoh M., Yamanaka H., Fukami T., Tokudome S., Yamamoto Y., Yamamoto H., and Yokoi T. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. J. Clin. Pharmacol. 46 (2006) 337-344
38. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., and Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24 (1996) 1212-1217
39. NSDUH, 2006. Past month cigarette use among racial and ethnic groups. The NSDUH Report.
40. Oscarson M., McLellan R.A., Asp V., Ledesma M., Bernal Ruiz M.L., Sinues B., Rautio A., and Ingelman-Sundberg M. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. 20 (2002) 275-283
41. Oscarson M., McLellan R.A., Gullsten H., Yue Q.Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., and Ingelman-Sundberg M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448 (1999) 105-110
42. Parkinson A., Mudra D.R., Johnson C., Dwyer A., and Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199 (2004) 193-209
43. Perez-Stable E.J., Herrera B., Jacob III P., and Benowitz N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280 (1998) 152-156
44. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., and Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284 (2001) 455-460
45. Prather R.D., Tu T.G., Rolf C.N., and Gorsline J. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J. Clin. Pharmacol. 33 (1993) 644-649
46. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27 (2004) 561-568
47. Richter K., Kaur H., Resnicow K., Nazir N., Mosier M.C., and Ahluwalia J.S. Cigarette smoking among marijuana users in the United States. Substance Abuse 25 (2005) 35-43
48. Rigotti N.A., Lee J.E., and Wechsler H. US college students' use of tobacco products: results of a national survey. JAMA 284 (2000) 699-705
49. Roth M.D., Marques-Magallanes J.A., Yuan M., Sun W., Tashkin D.P., and Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am. J. Respir. Cell Mol. Biol. 24 (2001) 339-344
50. Schachter S., Kozlo-ski L.T., and Silverstein B. 2. Effects of urinary pH on cigarette smoking. J. Exp. Psychol. Gen. 106 (1977) 13-19
51. Schoedel K.A., Hoffmann E.B., Rao Y., Sellers E.M., and Tyndale R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14 (2004) 615-626
52. Schoedel K.A., Sellers E.M., Palmour R., and Tyndale R.F. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol. Pharmacol. 63 (2003) 96-104
53. Schoedel K.A., Sellers E.M., and Tyndale R.F. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem. Pharmacol. 62 (2001) 1025-1036
54. Sellers E.M., Kaplan H.L., and Tyndale R.F. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68 (2000) 35-43
55. Sellers E.M., Lacaya L.B., and Kaplan H.L. A limited-sampling strategy for estimation of nicotine plasma area under the concentration versus time curve after oral nicotine (poster). Proceedings of the Society for Research on Nicotine and Tobacco. Scottsdale, Arizona (2004)
56. Sheweita S.A. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Toxicology 191 (2003) 133-142
57. Siu E.C., Wildenauer D.B., and Tyndale R.F. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl.) 184 (2006) 401-408
58. Strasser, A.A., Malaiyandi, V., Hoffmann, E.B., Tyndale, R.F., Lerman, C. An association of CYP2A6 genotype and smoking topography. Nicotine Tobacco Res., in press
59. Swan G.E., Benowitz N.L., Lessov C.N., Jacob III P., Tyndale R.F., and Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet. Genomics 15 (2005) 115-125
60. Tyndale R.F., Droll K.P., and Sellers E.M. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7 (1997) 375-379
61. USDHHS, 1998. Tobacco use among U.S. Racial/Ethnic Minority Groups: African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: a report of the surgeon general.
62. Van Vunakis H., Tashkin D.P., Simmons M., and Clark V.A. Decreased serum cotinine levels in smokers of both tobacco and marijuana as compared with smokers of tobacco only. Pharmacol. Biochem. Behav. 30 (1988) 895-898
63. Wang J., Pitarque M., and Ingelman-Sundberg M. 3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem. Biophys. Res. Commun. 340 (2006) 491-497
64. Wynn G.H., Cozza K.L., Zapor M.J., Wortmann G.W., and Armstrong S.C. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 46 (2005) 79-87
65. Wynne H. Drug metabolism and ageing. J. Br. Menopause Soc. 11 (2005) 51-56
66. Wynne H.A., Cope L.H., Mutch E., Rawlins M.D., Woodhouse K.W., and James O.F. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9 (1989) 297-301
67. Xu C., Rao Y.S., Xu B., Hoffmann E., Jones J., Sellers E.M., and Tyndale R.F. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun. 290 (2002) 318-324
68. Zawertailo L.A., Kaplan H.L., Busto U.E., Tyndale R.F., and Sellers E.M. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J. Clin. Psychopharmacol. 18 (1998) 332-337
69. Zeman M.V., Hiraki L., and Sellers E.M. Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J. Womens Health Gend. Based Med. 11 (2002) 147-153